Nan, Daniel and Abraira-Meriel, Cristina and de la Roz-Fernández, Sandra and Maestre-Orozco, Tamara and Hernandez, Jose Luis and Fernandez-Ayala, Marta (2021) Delayed Use of the Recombinant Human IL-1 Receptor Antagonist Anakinra in Five COVID-19 Patients with Pulmonary Fibrosis and Persistent Hypoxaemia: A Preliminary Report. European Journal of Case Reports in Internal Medicine, 8 (10). pp. 1-5. ISSN 2284-2594
|
Text
2821-Article Text-24755-1-10-20211006 (1).pdf - Published Version Download (521kB) | Preview |
Abstract
Coronavirus disease 2019 (COVID-19) is currently a major public health problem. The development of pulmonary fibrosis secondary to acute respiratory distress syndrome (ARDS) is one of the expected sequelae. In this case series, we describe five instances of the use of anakinra in late-phase COVID-19 pneumonia in hospitalized patients with pulmonary fibrosis and refractory respiratory failure fulfilling ARDS criteria. The study demonstrates that anakinra has promising efficacy and safety in late-phase COVID-19 infection in patients with ARDS and refractory hypoxaemia, and suggests its potential application as antifibrotic therapy in these patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Pulmonary fibrosis, COVID-19, anakinra |
| Subjects: | 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) |
| Depositing User: | Marina Spanti |
| Date Deposited: | 17 Feb 2022 12:08 |
| Last Modified: | 17 Feb 2022 12:08 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/21729 |
Actions (login required)
 |
View Item |
